Daré Bioscience, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on the stock and has a $12.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Douglas Tsao has given his Buy rating due to a combination of factors that highlight Daré Bioscience’s strategic positioning and growth potential. The anticipated launch of Sildenafil Cream in the fourth quarter of 2025 is a pivotal element, as it represents the company’s dual-path strategy aimed at generating short-term revenue. This product distinguishes itself in the market by being the only female arousal cream studied in a clinical trial, which is expected to convince healthcare professionals of its superiority over existing products.
Furthermore, Daré Bioscience’s collaboration with Rosy Wellness and its proactive pre-launch promotional activities underscore a robust marketing approach. The company’s engagement with healthcare professionals and its strategy to collect real-world evidence post-launch are designed to strengthen the product’s market acceptance and potential for regulatory approval. Additionally, Daré’s plans to introduce more products, such as non-prescription vaginal probiotics and the DARE-HRT1 hormone therapy, indicate a promising pipeline that could significantly expand its market presence and revenue streams.